Physician profile
Mark D Carlson
NPI 1184736498
$2,329.11
in general payments reported to CMS, 2019-2025
16 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $179 · 2021: $218 · 2022: $400 · 2023: $642 · 2024: $211 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173 · Gift: $164 · Education: $83.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.79 |
| Gift | $163.62 |
| Education | $83.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $410.69 | 2020-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $363.50 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $340.48 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.03 | 2020-2025 | Jardiance, Synjardy |
| Amgen INC. | $238.11 | 2022-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $185.14 | 2025 | Farxiga, Airsupra |
| Braintree Laboratories, INC. | $163.62 | 2023 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.01 | 2021-2024 | Xifaxan |
| Medtronic Vascular, INC. | $113.33 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.48 | 2022 | |
| Axsome Therapeutics, INC. | $25.55 | 2025 | Auvelity |
| Vertex Pharmaceuticals Incorporated | $21.07 | 2025 | |
| Pfizer INC. | $19.67 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.67 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.73 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.